The nutraceutical industry has long followed a straightforward process: an ingredient with a plausible safety record is selected, tested in trials, and marketed if early results appear encouraging. This method assumes effectiveness without rigorous proof and designs products based on broad population averages, which often fail to account for individual biological variations. While this approach has produced some beneficial products, it has also created a market where efficacy is unpredictable, evidence is frequently weak, and claims tend to be vague.
A fundamental change is now emerging. Instead of beginning with an ingredient and assessing its effects, the new strategy starts with the specific biological issue—whether it involves disrupted metabolic pathways, immune dysfunction, or microbial imbalances tied to particular health conditions. Ingredients are treated as tools to achieve precise biological outcomes rather than the primary focus. This evolution is largely driven by advances in gut microbiome research, which has demonstrated that microbial composition varies significantly between individuals due to factors like diet, geography, genetics, and environmental exposure.
A 2025 study published in Nature Microbiology illustrated this variability, showing that identical plant compounds can be metabolized differently depending on an individual’s microbiome. Most current nutraceutical formulations, however, are designed around average population data—a flawed assumption when gut microbes directly influence health outcomes such as metabolic regulation, immune function, neurological health, skin conditions, and even eye health.
Computational modeling reshapes microbiome-based designs
Computational modeling is now central to this transformation. Genome-scale metabolic modeling allows researchers to simulate how gut bacteria interact across thousands of real microbiome profiles, moving beyond broad population averages. These models identify disrupted metabolic pathways in specific conditions and determine which food-grade compounds can be converted by gut bacteria into essential molecules the body lacks.
At Enbiosis Biotechnology, this methodology is already in practice. The company creates a digital twin of the gut microbiome for targeted health conditions, runs simulations across diverse profiles, and designs formulations based on actual biological needs rather than generic wellness claims. An AI-driven retrosynthesis engine then identifies the minimal set of food-grade precursors required to produce the desired biological effect.
Related Post: Food Industry Moves AI Beyond Pilot Needs Governance
The first formulation developed through this approach addresses dry eye, a condition increasingly linked to gut microbiome composition. A prospective pilot study of a food-grade oral formulation targeting the gut–eye axis demonstrated meaningful changes across multiple clinical endpoints. Participants took the formulation once daily for eight weeks, with effects maintained through a follow-up assessment at week sixteen. A randomized controlled trial is now underway, with results awaiting peer review.
Targeted formulations for eye, skin, and brain health
This computational method extends beyond dry eye to conditions where gut microbes play a significant role. Active development targets metabolic health, particularly insulin resistance and blood sugar regulation, skin disorders like psoriasis, and neurological health, where microbial influences on cognitive function are gaining recognition. The process remains consistent: a digital twin is built for the condition, simulations are performed across diverse microbiomes, and formulations are tailored to address the specific biological mechanisms at play.
The transition from ingredient-focused to biology-driven formulation represents more than a theoretical shift. It alters how products are developed, what they are designed to achieve, and how their effects are measured and validated. While clinical evidence remains critical, the foundational approach, whether centered on biological targets or population averages, determines the legitimacy of efficacy claims.
For companies in this sector, the relevance of microbiome science is no longer in question. The necessary tools exist, evidence is accumulating, and the first products designed using this method are beginning to reach consumers. The pressing challenge is whether the industry can adapt quickly enough to meet the growing demands of regulators, retailers, and partners who now expect mechanism-driven, evidence-supported formulations.
The first products designed using this method are already available, and the framework is being applied to metabolic health, dermatological conditions, and neurological targets. The defining difference lies in the starting point: no longer an ingredient, but a biological problem, and a formulation engineered to resolve it.